Regeneron: Covid-19 prevention trial begins
(CercleFinance.com) - Regeneron Pharmaceuticals has announced starting a Phase III clinical trial for REGN-COV2 for the prevention of Covid-19, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
This trial will evaluate the ability of this experimental "cocktail" of two antibodies to prevent infection in people who have been highly exposed to Covid-19 patients. It will be conducted at about 100 sites and is expected to recruit 2,000 patients in the United States.
REGN-COV2 has also entered part II/III of two adaptive Phase I/II/III trials testing its ability to treat both inpatients and outpatients with Covid-19, following a positive Phase I safety review.
Copyright (c) 2020 CercleFinance.com. All rights reserved.